Zheng Quan Zhi Xing·2025-09-01 16:10Group 1 - Shanghai Pharmaceutical Group Co., Ltd. announced that its subsidiary, Shanghai Hefeng Pharmaceutical Co., Ltd., has received approval from the National Medical Products Administration for the consistency evaluation of the quality and efficacy of Verapamil Hydrochloride Injection [1][2] - The drug is primarily used for the rapid conversion of paroxysmal supraventricular tachycardia and for temporary control of ventricular rate in atrial flutter or atrial fibrillation [1][2] - The company has invested approximately RMB 3.29 million in research and development for this drug's consistency evaluation [1] Group 2 - As of the announcement date, there is one other company, Sichuan Meida Kangjiale Pharmaceutical Co., Ltd., that has also been deemed to have passed the consistency evaluation for this drug in China [2] - The IQVIA database indicates that the total procurement amount for Verapamil Hydrochloride Injection in hospitals in mainland China for 2024 is RMB 148.51 million [2] - The approval for consistency evaluation is expected to enhance the market share and competitiveness of Shanghai Hefeng's Verapamil Hydrochloride Injection, while also providing valuable experience for future product evaluations [2]